TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21791425
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2; median number of infused NK cells was 2.74 × 10(6)/Kg; T cells were < 10(5)/Kg.
Study: 21791469
Drug: Bortezomib treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib treatment
Study: 21791473
Drug: Deferiprone 15
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 15 mg/kg bid
Study: 21791475
Drug: Cytarabine 400
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 400 mg/m(2)/day for 5 days + Tanespimycin 300 mg/m(2) on days 3 and 6
Study: 21791513
Drug: Oral antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antiplatelet therapy (OAT) interruption for more than 5 days prior to surgery
Study: 21791513
Drug: Preoperative haemoglobin
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative haemoglobin <10 g/dl
Study: 21791513
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance <30 ml/min
Study: 21791513
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance between 30 and 60 ml/min
Study: 21791540
Drug: Plasma NGAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma NGAL and BNP combination
Study: 21794112
Drug: Solutions implemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutions implemented in the study
Study: 21794906
Drug: Food Allergy
Normalized name: Nutritional Supplement Oral Powder for Suspension [FOOD ALLERGY FORMULA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food Allergy Herbal Formula-2 (FAHF-2), 3.3 g (6 tablets) three times a day for 6 months
Study: 21795476
Drug: ABT-888 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan (0.6 mg/m²/d) on days one to five of 21-day cycles
Study: 21795476
Drug: ABT-888 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan
Study: 21799479
Drug: Leptin levels
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin levels (ng/ml)
Study: 21801604
Drug: Cervarix vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix vaccine (three doses in Months 0, 1, and 6)
Study: 21802924
Drug: Hydro-alcoholic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydro-alcoholic extract of Lippia alba leaves, administered orally for 30-60 days.
Study: 21807867
Drug: Copeptin <14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin <14 pmol/L plus hscTnT <14 ng/L
Study: 21812576
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) levels on admission
Study: 21812736
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg once daily for 12 weeks
Study: 21812736
Drug: Ambrisentan 10
Normalized name: ambrisentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 10 mg once daily for an additional 12 weeks
Study: 21812736
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg and 10 mg
Study: 21812775
Drug: Sumavel DosePro
Normalized name: Sumavel DosePro
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumavel DosePro (needle-free subcutaneous sumatriptan) 6 mg
Study: 21812991
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) with therapist support for 15 weeks
Study: 21812991
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) with therapist support
Study: 21815133
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m² on days 1, 8, and 15 of a 28-day cycle
Study: 21815182
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of decitabine, arsenic trioxide, and ascorbic acid
Study: 21815705
Drug: Atorvastatin lactone
Normalized name: citronellene lactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin lactone to atorvastatin acid ratio with a cut-off ratio set at 1.1
Study: 21816031
Drug: RTS, S
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS, S malaria candidate vaccine
Study: 21816032
Drug: RTS,S/AS01 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 malaria candidate vaccine
Study: 21818676
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), 80 sessions
Study: 21819507
Drug: Intravitreal EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal EPO injection (1000 IU/0.05 mL)
Study: 21821712
Drug: Cladribine 5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 5.6 mg/m² IV over 2 hours daily for 5 days followed by rituximab 375 mg/m² IV weekly for 8 weeks
Study: 21823912
Drug: Aripiprazole (APZ)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (APZ) at flexible doses (maximum 15 mg/day) for up to 16 weeks
Study: 21824458
Drug: Short half-life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short half-life antidepressants
Study: 21824458
Drug: Antidepressant exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant exposure
Study: 21824458
Drug: Overall antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antidepressant exposure
Study: 21826527
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m²) on Day 1, vinorelbine (27.5 mg/m²) on Days 8 and 15, filgrastim (5 µg/kg) on Days 2-21, and weekly trastuzumab (2 mg/kg after an initial bolus of 4 mg/kg)
Study: 21828124
Drug: Blocking of
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking of VLA-4 signaling in combination with cytarabine treatment
Study: 21828141
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m², four weekly applications)
Study: 21828142
Drug: Anti-PDGFRA antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PDGFRA antibodies
Study: 21831297
Drug: Transdermal rotigotine
Normalized name: rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rotigotine patch (dosage ratio of 1.5:1)
Study: 21831297
Drug: Oral ropinirole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ropinirole
Study: 21831685
Drug: Voriconazole therapy
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole therapy
Study: 21831954
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg QD
Study: 21831954
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg QD
Study: 21831954
Drug: Pazopanib (200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (200-800 mg)
Study: 21835005
Drug: Age ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age ≥ 51 years, prior neurologic damage, immunosuppression, combination of abnormal white blood cells (WBC) and elevated RDW
Study: 21835005
Drug: Post chest
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post chest radiation state, prior neurologic damage, blood urea nitrogen (BUN) > 10.7 mmol/L, RDW > 14.5%
Study: 21835825
Drug: ASA404 (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (1800 mg/m²) plus docetaxel (75 mg/m²)
Study: 21835825
Drug: ASA404 (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (1800 mg/m²) plus docetaxel (60 mg/m²)
Study: 21838412
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg orally once daily for days 1 to 3; 0.5 mg twice daily for days 4 to 7; 1 mg twice daily for the remainder of a 12-week treatment period)
Study: 21840522
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for analgesic treatment
Study: 21841163
Drug: Clofarabine combined
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine combined with myeloablative doses of busulfan
Study: 21846371
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d reduced viscosity barley β-glucan (BBG)
Study: 21846371
Drug: 6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/d reduced viscosity barley β-glucan (BBG)
Study: 21846636
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (TIV)
Study: 21849481
Drug: Intervention therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention therapy for life-threatening symptoms (n = 29/38; 76%)
Study: 21850464
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and temozolomide (MTDs: 1.3 mg/m² for bortezomib and 200 mg/m² for temozolomide)
Study: 21851846
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation antipsychotics (SGA) treatment
Study: 21854593
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic treatment with clindamycin and metronidazole plus vaginal gelatine capsules containing different strains of lactobacilli (109 freeze-dried bacteria per capsule)
Study: 21855974
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-Endometrial (FACT-En)
Study: 21857286
Drug: Didanosine, lamivudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine, lamivudine, efavirenz (once-daily administration)
Study: 21857490
Drug: Darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (DRV/r) 800/100 mg once daily and Raltegravir (RAL) 400 mg twice daily
Study: 21859692
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg or 2 mg/kg (≤40 kg) subcutaneously every 8 weeks for up to 2 years
Study: 21859696
Drug: Adjuvant-free influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine
Study: 21860633
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 1-month depot administered intramuscularly every 28 days.
Study: 21861537
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg once-daily
Study: 21861537
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once-daily
Study: 21861537
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin/warfarin
Study: 26510020
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg twice a day
Study: 21865346
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg once-daily dosing
Study: 21867401
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) 1.3 g administered three-times daily for up to 5 days per menstrual cycle (maximum of 15 doses)
Study: 21867539
Drug: Nurse-led, interprofessional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led, interprofessional mental health promotion intervention (6-month program with regular home visits and monthly case conferences)
Study: 21868014
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with genetic variant analysis for COQ2 (rs4693570)
Study: 21868014
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with genetic variant analysis for ATP2B1 (rs17381194)
Study: 21868014
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with genetic variant analysis for DMPK (rs672348)
Study: 21868572
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of donor T cells (2 × 10(8)/kg)
Study: 21868778
Drug: Low glucose
Normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucose suspend (LGS) feature of the Paradigm Veo insulin pump
Study: 21869687
Drug: Vilazodone 40
Normalized name: vilazodone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone 40 mg/d for 1 year
Study: 21871057
Drug: Walnut oil
Normalized name: Walnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut oil (0.5 mg/mL)
Study: 21874317
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic cyclophosphamide (CTX) 65 mg/m² daily on days 1-14 plus capecitabine 1,000 mg/m² twice daily on days 1-14, repeated every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: 21876119
Drug: Hydroxyurea therapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy at maximum tolerated dose (MTD)
Study: 21877169
Drug: Eculizumab, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab, 600 mg every 2 weeks
Study: 21877169
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (initial treatment)
Study: 21877508
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate spray 0.05% in the morning and calcitriol ointment 3 microg/g in the evening for up to 4 weeks
Study: 21880803
Drug: 1-year lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year lifestyle intervention (nutrition education, exercise training, behavior therapy)
Study: 21884952
Drug: Strain-encoded magnetic
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strain-encoded magnetic resonance imaging (SENC) during high-dose dobutamine stress cardiac magnetic resonance imaging (DS-MRI)
Study: 21887501
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m2
Study: 21887501
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 0.7-2.0 mg/m2
Study: 21888637
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m² IV on days 1 and 8) and capecitabine (900 mg/m² orally twice a day on days 1-14)
Study: 21888637
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel and capecitabine
Study: 21889330
Drug: Axitinib (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5mg twice daily)
Study: 21890206
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (IV NAC)
Study: 21890206
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine (oral NAC)
Study: 21892005
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) administered in 3 doses at 0, 1, and 6 months
Study: 21895032
Drug: Electrochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemotherapy with intravenous bolus injection of bleomycin and electric pulses delivered via long needle electrodes
Study: 21895536
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of the oncolytic herpes virus NV1020
Study: 21898376
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg once-daily
Study: 21900113
Drug: RG7160 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks
Study: 21900189
Drug: Thalidomide-dexamethasone (TD)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide-dexamethasone (TD) induction therapy and double autotransplantation (ASCT)
Study: 21901296
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections (3 monthly injections)
Study: 21903775
Drug: Purified irradiated
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified irradiated PfSPZ administered by needle inoculation in the skin
Study: 21903775
Drug: Intravenous immunization
Normalized name: GLOBULIN,IMMUNE (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunization of PfSPZ
Study: 21904098
Drug: MS-sNT (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-sNT (morphine sulfate and sequestered naltrexone)
Study: 21909835
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous levetiracetam (LEV)
Study: 21911742
Drug: VLDL-TG storage
Normalized name: polyester-5 (TG-48)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLDL-TG storage in upper-body subcutaneous (UBSQ) fat
Study: 21911742
Drug: VLDL-TG storage
Normalized name: polyester-5 (TG-48)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLDL-TG storage in lower-body subcutaneous (LBSQ) fat
Study: 21911830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of romidepsin, bortezomib, and dexamethasone
Study: 21911830
Drug: Maintenance romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance romidepsin 10 mg/m(2)
Study: 21913066
Drug: Biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agents (monoclonal antibodies anti-TNF: infliximab and adalimumab; others: abatacept and tocilizumab)
Study: 21915260
Drug: sirolimus, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus, daily for 52 weeks
Study: 21916630
Drug: Citalopram (antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (antidepressant medication)
Study: 21917896
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment with undetectable HIV RNA levels
Study: 21921042
Drug: Baseline (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (before hydroxyurea therapy)
Study: 21921761
Drug: Carbon dioxide-based
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide-based tissue expander with daily administration of small doses of carbon dioxide via a hand-held dosage controller.
Study: 21923942
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural infusion (EI) with ropivacaine 0.2% 3-8 mL/h and fentanyl 2 μg/mL
Study: 21923942
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min
Study: 21923942
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 10 μg/ml postoperatively 3-8 mL/h (Control group)
Study: 21927046
Drug: Interventional techniques
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional techniques with safe injection practices and single dose vials for multiple patients
Study: 21930881
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg by mouth twice daily
Study: 21930881
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of oseltamivir
Study: 21931054
Drug: Pulsed-dye laser
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed-dye laser treatment
Study: 21931054
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream
Study: 21931113
Drug: Dasatinib induction
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy
Study: 21931113
Drug: Dasatinib induction
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib induction therapy
Study: 21931634
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of E. coli lipopolysaccharide (LPS) 0.3 ng/kg
Study: 21932952
Drug: Desirudin (Iprivask®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (Iprivask®, Canyon Pharmaceuticals™)
Study: 21935635
Drug: TSU-68, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSU-68, a multiple tyrosine kinase inhibitor
Study: 21935916
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m(2) administered intravenously on days 1 and 8 every 21 days in platinum-resistant cohort